CR-CHOP+X in Previously Untreated DEL
ConditionDLBCL
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorRuijin Hospital
About this trial
This is a prospective, single-arm, open-label phase II clinical trial that evaluates the efficacy and safety of CR-CHOP regimen combined with different targeted drugs based on different molecular subtypes in newly diagnosed DEL patients.
Eligibility criteria
Qualifiers
1. Histologically confirmed diffuse large B-cell lymphoma with CD20 positive;
2. MYC and BCL2 are expressed simultaneously, WHO immunohistochemical standards: MYC≥40%, BCL2 ≥50%;
3. Age ≥ 18 years old, ≦75 years old;
4. ECOG physical status score of 0, 1 or 2;
Disqualifiers
1. Have previously received systemic or local treatment including chemotherapy;
2. Previously received autologous stem cell transplantation;
3. Previous history of other malignant tumors, except skin basal cell carcinoma and cervical carcinoma in situ;
4. Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, serious infectious diseases and other diseases;
Trial design
Treatments tested in this trial
- CR-CHOP+PD1 inhibitor
- CR-CHOP + Orelabrutinib
- CR-CHOP + decitabine
Treatment groups
49 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov